NR PLUS Regulatory Policy The FTC Should Keep Its Hands Off Innovative Biopharma Mergers By Alden Abbott February 21, 2022 A crackdown on biopharma mergers led by the FTC could undermine future accomplishments, harming the American economy and patents.
Regulatory Policy New Antitrust Bills — Anti-Consumer, Anti-Enterprise, and Anti-Innovation By Alden Abbott & Andrew Mercado October 28, 2021 The proposals toss antitrust’s proper concern to the side and focus exclusively on the market’s biggest actors.
Regulatory Policy The FTC’s Repeal of Enforcement Guidance Is Bad News for Business By Alden Abbott & Andrew Mercado July 21, 2021 Without the proper guardrails guiding the agency’s hand, there will likely be major losses for the competitive health of the American economy.
Regulatory Policy The Internet Doesn’t Need Heavy-Handed Regulation By Alden Abbott & Andrew Mercado June 10, 2021 A Facebook VP’s proposal to regulate the Internet would undermine competition, innovation, and free speech.
Capital Matters Waiving IP Protection for COVID Vaccines Is Anti-innovation and Anti–Public Health By Alden Abbott May 7, 2021 Patent rights were key to the unprecedentedly rapid development and rollout of COVID-19 vaccines.
Regulatory Policy Antitrust Should Stay Focused on Consumer Welfare By Alden Abbott & Tracy C. Miller April 2, 2021 Antitrust attacks aimed at ‘cutting monopoly platforms down to size’ harm consumers.